Blogs

December 22, 2022

Enhancing Diabetic Wound Healing Through Injectable Hydrogel Innovation

Arni Medica, in collaboration with JSS University, continues to pioneer advanced therapeutic solutions for diabetic wounds (DWs). A recent breakthrough involves the development of a thermo-responsive injectable hydrogel, enriched with Epidermal Growth Factor (EGF) and Doxycycline (DOX). This innovative hydrogel, designed to address the multifaceted challenges of DWs, demonstrates exceptional potential in accelerating healing and minimizing complications.

The injectable hydrogel encapsulates EGF and DOX within chitosan-based nanoparticles, enhancing drug stability and ensuring controlled, sustained release. EGF facilitates critical stages of wound healing, including cell proliferation, granulation tissue formation, and collagen synthesis, while DOX provides robust antibacterial and anti-inflammatory properties.


Key Research Outcomes:

  • Enhanced Healing: In vivo studies revealed rapid wound closure, reduced inflammation, and minimized ulceration compared to traditional treatments.
  • Superior Biocompatibility: The hydrogel demonstrated excellent cytocompatibility with fibroblast cells, crucial for wound regeneration.
  • Controlled Drug Release: Sustained release of EGF over five days ensures prolonged therapeutic effects, while DOX offers immediate antibacterial action against pathogens like S. aureus and E. coli.
  • Histological Evidence: Treated wounds exhibited enhanced re-epithelialization, fibroblast activity, and collagen deposition, crucial for effective healing.

This cutting-edge research, published in Gels (DOI: 10.3390/gels9010027), underscores Arni Medica's commitment to revolutionizing wound care through innovation. The thermo-responsive hydrogel represents a significant step forward in addressing the global burden of diabetic wounds, offering hope for improved patient outcomes and reduced healthcare costs.

We are here to help you

CAREERS CONTACT US